Targeting the Apoptosis-Resistant Pulmonary Myofibroblast
Targeting the Apoptosis-Resistant Pulmonary Myofibroblast
批准号:
8371194
负责人:
James S. Hagood
金额:
$38.39万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-08-01 至 2016-05-31
关键词:
AdhesionsAnimal ModelApoptosisApoptoticBiologyBleomycinCell SurvivalCell surfaceCellsCessation of lifeCicatrixCouplingDataDevelopmentDiseaseFibroblastsFibrosisFocal Adhesion Kinase 1Growth FactorHamman-Rich syndromeHeterogeneityHistologicHumanIn VitroIncidenceIndividualIntegrinsInterventionKnowledgeLaboratoriesLesionLungLung diseasesMechanicsMediatingMediator of activation proteinMembrane GlycoproteinsMembrane MicrodomainsModelingMolecularMusMuscleMyofibroblastPathogenesisPathway interactionsPhenotypePre-Clinical ModelProteinsReportingResistanceRodentSignal PathwaySignal TransductionTestingTherapeuticTherapeutic AgentsTherapeutic InterventionTimeTissuesTransforming Growth Factor betaTranslatingTranslationsTumor Suppressor ProteinsWorkbasecytokinefibrogenesisimprovedin vivoin vivo Modelinnovationmigrationmortalitymouse modelnovel strategiesnovel therapeutic interventionnovel therapeuticsoutcome forecastsrc-Family Kinasessyndecan-4transcription factor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Idiopathic pulmonary fibrosis (IPF) is an incurable fatal disease with increasing incidence and mortality. Despite recent coordinated attempts to rapidly translate findings which have been validated in vitro and in preclinical models into biologically promising interventions, there have been no major therapeutic breakthroughs. A final common pathway for the destructive remodeling which characterizes fibrosis is the apoptosis-resistant myofibroblast, which both creates and responds to an altered mediator and matrix microenvironment, thus perpetuating fibrogenesis. Halting the development of the myofibroblast phenotype, or reversing it once established, offers the best hope of successfully treating IPF. The cell surface glycoprotein Thy-1, a known tumor suppressor which acts as a context-dependent regulator of cell phenotype, is silenced in the myofibroblasts within fibroblastic foci, the signature histopathologic lesions in IPF, the presence of which portends a poor prognosis. Absence of Thy-1 in cultured lung fibroblasts promotes proliferation, cytokine and growth factor expression and responsiveness, migration, myofibroblastic differentiation, and resistance to apoptosis, all reversible upon re-expression of Thy-1. Thy-1 interacts with alpha v integrins and syndecan 4 at the cell surface, modulating cell-cell and cell-matrix interactions and
mechanical coupling, to inhibit TGF-beta activation and myofibroblastic differentiation. The effects of Thy-1 on the myofibroblast phenotype are broad, including: decreased expression of a number of muscle-specific proteins and myogenic transcription factors, inhibition of contractility,
and promotion of apoptosis. Furthermore, some of the functions of Thy-1 can be recapitulated by the administration of soluble Thy-1, and preliminary data demonstrate that soluble Thy-1 reverses established fibrosis in a mouse model, indicating that Thy-1 itself can be used or modified for therapeutic benefit. Taken together, this knowledge leads us to the overall hypothesis that Thy-1-mediated signaling broadly suppresses myofibroblastic transformation and promotes apoptosis, restoring homeostatic function in lung fibroblasts. Improved understanding of the molecular mechanisms involved will uncover novel strategies for reversing the pathogenic myofibroblast phenotype in IPF and other fibrotic disorders. In vitro and in vivo models based on heterogeneity and targeted disruption of Thy-1 offer excellent opportunities for defining myofibroblast-targeting strategies, as outlined in the following specific aims: Aim 1: To define the mechanisms by which Thy-1- inhibits myofibroblastic differentiation of lung fibroblasts; Aim 2: To define the mechanisms by which Thy-1 promotes myofibroblast apoptosis; and Aim 3: To harness Thy-1-modulated signaling to reverse the apoptosis-resistant myofibroblast phenotype in vivo. Significance: Because Thy-1 modulates multiple signaling pathways critical to fibrogenesis, capitalizing on its function is more attractive than targeting a
single pathway, which has been shown to be an ineffective approach in IPF. The proposed studies will thus define mechanisms by which Thy-1 suppresses profibrotic differentiation of lung fibroblasts, and translate that knowledge into innovative therapeutic interventions for fibrotic lung disease.
PUBLIC HEALTH RELEVANCE: Targeting individual signaling pathways has failed time and again in treating idiopathic pulmonary fibrosis (IPF), a fatal and progressive lung disease which is increasing in incidence. The differentiation of a structural cell in the lung known as the fibroblast into the aggressive scar-forming myofibroblast, which resists programmed cell death (apoptosis) and gradually replaces the lung with scar tissue, is central to the pathogenesis of IPF. Restoring or replacing the function of Thy-1, a fibroblast molecule that globally suppresses the apoptosis-resistant myofibroblast phenotype, offers the best hope for treating this devastating disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
KULMAP: Human Kidney, urinary tract and lung mapping center
-
批准号:9987373
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2019
-
负责人:James S. Hagood
-
依托单位:
KULMAP: Human Kidney, urinary tract and lung mapping center
-
批准号:10413576
-
项目类别:
-
资助金额:$10.0万
-
财政年份:2018
-
负责人:James S. Hagood
-
依托单位:
Organ Specific Project
-
批准号:10237125
-
项目类别:
-
资助金额:$31.05万
-
财政年份:2018
-
负责人:James S. Hagood
-
依托单位:
KULMAP: Human Kidney, urinary tract and lung mapping center
-
批准号:10237122
-
项目类别:
-
资助金额:$184.85万
-
财政年份:2018
-
负责人:James S. Hagood
-
依托单位:
KULMAP: Human Kidney, urinary tract and lung mapping center
-
批准号:9791201
-
项目类别:
-
资助金额:$100.0万
-
财政年份:2018
-
负责人:James S. Hagood
-
依托单位:
Targeting the Apoptosis-Resistant Pulmonary Myofibroblast
-
批准号:8677065
-
项目类别:
-
资助金额:$6.98万
-
财政年份:2012
-
负责人:James S. Hagood
-
依托单位:
Childhood Interstitial & Diffuse Lung Disease Scientific Conference
-
批准号:8319294
-
项目类别:
-
资助金额:$2.3万
-
财政年份:2012
-
负责人:James S. Hagood
-
依托单位:
Targeting the Apoptosis-Resistant Pulmonary Myofibroblast
-
批准号:8516090
-
项目类别:
-
资助金额:$36.63万
-
财政年份:2012
-
负责人:James S. Hagood
-
依托单位:
Epigenetic Alterations in IPF Fibroblastic Foci
-
批准号:7712750
-
项目类别:
-
资助金额:$7.32万
-
财政年份:2009
-
负责人:James S. Hagood
-
依托单位:
Regulation of Fibroblast Phenotype in Lung Fibrosis
-
批准号:7824718
-
项目类别:
-
资助金额:$1.81万
-
财政年份:2009
-
负责人:James S. Hagood
-
依托单位:
Regulation of Fibroblast Phenotype in Lung Fibrosis
-
批准号:7318994
-
项目类别:
-
资助金额:$35.85万
-
财政年份:2007
-
负责人:James S. Hagood
-
依托单位:
Regulation of Fibroblast Phenotype in Lung Fibrosis
-
批准号:9291496
-
项目类别:
-
资助金额:$33.48万
-
财政年份:2007
-
负责人:James S. Hagood
-
依托单位:
Regulation of Fibroblast Phenotype in Lung Fibrosis
-
批准号:7894813
-
项目类别:
-
资助金额:$38.6万
-
财政年份:2007
-
负责人:James S. Hagood
-
依托单位:
Regulation of Fibroblast Phenotype in Lung Fibrosis
-
批准号:7645802
-
项目类别:
-
资助金额:$36.31万
-
财政年份:2007
-
负责人:James S. Hagood
-
依托单位:
Regulation of Fibroblast Phenotype in Lung Fibrosis
-
批准号:8787052
-
项目类别:
-
资助金额:$42.6万
-
财政年份:2007
-
负责人:James S. Hagood
-
依托单位:
Regulation of Fibroblast Phenotype in Lung Fibrosis
-
批准号:8890859
-
项目类别:
-
资助金额:$54.84万
-
财政年份:2007
-
负责人:James S. Hagood
-
依托单位:
Regulation of Fibroblast Phenotype in Lung Fibrosis
-
批准号:7483042
-
项目类别:
-
资助金额:$36.37万
-
财政年份:2007
-
负责人:James S. Hagood
-
依托单位:
Role of Fibroblast Thy-1 in Pulmonary Fibrosis
-
批准号:6473087
-
项目类别:
-
资助金额:$24.48万
-
财政年份:2002
-
负责人:James S. Hagood
-
依托单位:
Role of Fibroblast Thy-1 in Pulmonary Fibrosis
-
批准号:6624221
-
项目类别:
-
资助金额:$26.12万
-
财政年份:2002
-
负责人:James S. Hagood
-
依托单位:
Role of Fibroblast Thy-1 in Pulmonary Fibrosis
-
批准号:6613065
-
项目类别:
-
资助金额:$0.75万
-
财政年份:2002
-
负责人:James S. Hagood
-
依托单位:
海外基金